Press Release Details

Cerus Corporation Stock Trading Halted; FDA Blood Products Advisory Committee to Review and Discuss Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System

November, 16 2009

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today that NASDAQ has halted trading of Cerus common stock.

The U.S. Food and Drug Administration's (FDA) Blood Products Advisory Committee (BPAC) is meeting today to review and discuss the proposed design for a potential U.S. Phase III clinical trial of platelets treated with the Company's INTERCEPT Blood System.


Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is currently in clinical development. See for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

    Source: Cerus Corporation

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600